BeiGene’s late stage trial shows promising numbers; Amgen to study sotorasib dosage after FDA recommendation

Big Chinese pharma player BeiGene $BGNE is showing off some promising numbers from its interim analysis of a late-stage, head-to-head trial pitting their BTK drug Brukinsa (zanubrutinib) against Imbruvica.

Reporting on 415 of 652 patients in the ALPINE...

Click to view original post